RICHLAND, WASHINGTON – September 16, 2020 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori...
RICHLAND, WASHINGTON – October 29, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR) announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is scheduled to take place...
Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, WASHINGTON – September 24, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...
Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2% Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date RICHLAND, WASHINGTON – September 18, 2019 –A recent publication is drawing attention for its positive report on a...
Conference Call is Tuesday, September 24, 2019, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
RICHLAND, WASHINGTON – September 10, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced today that it will spotlight the growing cancer...
RICHLAND, WASHINGTON – August 13, 2019 – Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.'s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for cancer...
New Brand Identity to Be Unveiled Thursday, June 13 RICHLAND, WASHINGTON – June 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced...
Record Revenue and Gross Profit Revenue Increased 22% Year-Over-Year RICHLAND, WASHINGTON – May 9, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...
Conference Call is May 9 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 1, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it...
RICHLAND, WASHINGTON – April 16, 2019 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced a new training collaboration with Texas Oncology. The...
Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year RICHLAND, WASHINGTON - February 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
Conference Call is February 12 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – January 30, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today...